



Dr. Pierre Laneuville is an Associate Professor (GFT-U) in the Department of Medicine and Oncology at McGill University and the former Head of Haematology for the McGill University Health Centre.

Dr. Laneuville obtained an Honours B.Sc. at McMaster University, his medical degree at the University of Ottawa, trained in internal Medicine at McGill University, and completed his haematology sub-specialty and research training with Dr. B.A. Cooper at the Royal Victoria Hospital and McGill

University from 1985 to 1989.

He then joined the staff and faculty at the Royal Victoria Hospital and McGill University and has focused his clinical and laboratory research activities on haematological malignancies.

Dr. Laneuville is best known for his research on the molecular mechanisms underlying the genesis and transformation of chronic myelogenous leukemia. He has served on numerous basic and clinical research panels including the Medical Research Council of Canada, the Leukemia Research Fund of Canada, the National Cancer Institute of Canada Clinical Trials Haematology Executive, and the Canadian Blood and Marrow Transplant Group.

Dr. Laneuville serves on the Honorary Medical Board of the Leukemia Research Fund of Canada, and is a member of various Ministerial Advisory Committees related to blood transfusion and transfusion safety.



Dr. Tan Soo Yong obtained his medical qualifications from the National University of Singapore and thereafter underwent postgraduate training in Forensic Pathology and Histopathology in Singapore and in the University of Sheffield, United Kingdom.

Qualifying in both forensic and histopathology, he is a Fellow of the Royal College of Pathologists (UK) and a Diplomate of the Society of Apothecaries of London.

Dr. Tan obtained his PhD from Oxford University, working in the field of haematopathology. His current research interest is in the pathology of NK/T cell lymphoma and Type II Enteropathy-associated T-cell lymphoma (Type II EATL).

He is a member of the International Lymphoma Study Group (ILSG) and a member of the team responsible for updating the WHO Classification of haematolymphoid neoplasms.

Dr. Tan sits on the Editorial Board of two pathology journals (Journal of Clinical Pathology, Biobanking and Biopreservation).

He is currently Associate Professor in the National University of Singapore Yong Loo Lin School of Medicine and Senior Consultant in the Department of Pathology, National University Hospital.

+ DR. TAN SOO YONG

+ PROF. CLAIR HARRISON

Professor Clair Harrison is Consultant Haematologist, Guy's and St Thomas Hospital, London, UK since 2001. Currently Clinical Director for Haematology, Palliative Care and Pathology. She was clinical lead for haematology from 2008-2013 Deputy clinical director cancer, haematology and palliative care from 2014-2016. She is deputy lead for haematology King's Health Partners 2011 to date.

She has a vast national/international leadership experience, being Founding member and co-chair MPNVoice charity 2004-date.

She chaired London Regional Blood Transfusion Committee from 2008-2012 & was Deputy Chair National Blood Transfusion Committee from 2012-2014. She Co-chaired European strategic working party MPN 2012 3 international meetings, scientific collaboration, support EU patient advocacy.

She is also elected trustee British Society of Haematology 2016. She is part of editorial Board of 4 & associate editor of 2 journals. She has 173 articles in journals including New England Journal of Medicine, Lancet, Nature, Nature Medicine, British Medical Journal, and specialty journals such as Blood, Leukaemia, Haematological. With 401 citable outputs. Her H-index is 50 and i10 index 109, 11018 citations, 7596 since 2011.



+ EVENT LOCATION (MAP)

TASJIN/1 MY1708684229



For Healthcare Professionals only.
For full prescribing information, please contact:



Novartis Corporation (Malaysia) Sdn Bhd (10920H)
Level 22, Tower B, Plaza 33, No.1, Jalan Kemajuan, Seksyen
13, 46200 Petaling Jaya, Selangor Darul Ehsan, Malaysia.
Tel: 03-7948 1888 Fax: 03-7948 1818 www.novartis.com



In Collaboration With:

**Malaysian
Society of
Haematology**

PROGRAM

8:30 AM - 8:55 AM	Registration		
8:55 AM - 9:00 AM	House Keeping & Other Announcements		
9:00 AM - 12:00 PM	Management of CML in the Era of Treatment Free Remission		Chairperson: Dr. Ng Soo Chin
9:00 AM - 9:30 AM	Monitoring Milestones: Why EMR is Important and its Relevance to DMR		Dr. Pierre Laneuville (Canada)
9:30 AM - 10:00 AM	Switch: 1st Gen TKI to 2nd Gen TKI, when and why?		
10:00 AM - 10:30 AM	Treatment-Free Remission in CML: Emerging Data and Considerations for Treatment Selection		
10:30 AM - 10:40 AM	Concluding Remarks by Chairperson		Chairperson: Dr. Ng Soo Chin Consultant Haematologist - SDMC
10:40 AM - 11:00 AM	Tea Break		
11:00 AM - 11:35 AM	Interactive Case Discussion: Case 1	Dr. Leong Tze Shin - SGH	Expert Panel: Dr. Ng Soo Chin, Dr. Pierre Laneuville
11:35 AM - 12:10 PM	Interactive Case Discussion: Case 2	Dr. Lim Soo Min Consultant Haematologist - HSA	
12:10 PM - 01:15 PM	Lunch & Hotel Check Out		
01:15 PM - 05:00 PM	Managing MPN: The Era of Targeted Therapies		Chairperson: Dato Dr. Chang Kian Meng
01:15 PM - 01:45 PM	Evolving Diagnosis of MPN		Dr. Tan Soo Yong (Singapore)
01:45 PM - 02:15 PM	MF - Long Term Treatment Benefits with Targeted Therapies		Prof. Clair Harrison (UK) (Webcast)
02:15 PM - 02:45 PM	Optimal Management of ICPV		
02:45 PM - 03:15 PM	Recent Updates in ET		
03:15 PM - 03:25 PM	Concluding Remarks by Chairperson		Dato Dr. Chang Kian Meng Consultant Haematologist - Hospital Ampang
03:25 PM - 03:45 PM	Tea Break		
03:45 PM - 04:20 PM	Interactive Case Discussion: Case 1	Dr. Azlan Husin Consultant Haematologist - HUSM	Expert Panel: Dato Dr. Chang, Dr. Tan & Prof. Harrison
04:20 PM - 03:55 PM	Interactive Case Discussion: Case 2	Dr. Adila - UMMC	
04:55 PM - 05:00 PM	Closing & End		